ID   IL7RA_HUMAN             Reviewed;         459 AA.
AC   P16871; B2RCS6; B4DVT1; Q05CU8; Q6NSP4; Q6NWM0; Q6NWM1; Q6NWM2; Q6NWM3;
AC   Q6SV45; Q9UPC1;
DT   01-AUG-1990, integrated into UniProtKB/Swiss-Prot.
DT   12-SEP-2018, sequence version 3.
DT   07-APR-2021, entry version 209.
DE   RecName: Full=Interleukin-7 receptor subunit alpha;
DE            Short=IL-7 receptor subunit alpha;
DE            Short=IL-7R subunit alpha;
DE            Short=IL-7R-alpha;
DE            Short=IL-7RA;
DE   AltName: Full=CDw127;
DE   AltName: CD_antigen=CD127;
DE   Flags: Precursor;
GN   Name=IL7R;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), ALTERNATIVE SPLICING, AND VARIANTS
RP   THR-66; ILE-138 AND VAL-356.
RC   TISSUE=B-cell;
RX   PubMed=2317865; DOI=10.1016/0092-8674(90)90342-c;
RA   Goodwin R.G., Friend D., Ziegler S.F., Jerzy R., Falk B.A., Gimpel S.,
RA   Cosman D., Dower S.K., March C.J., Namen A.E., Park L.S.;
RT   "Cloning of the human and murine interleukin-7 receptors: demonstration of
RT   a soluble form and homology to a new receptor superfamily.";
RL   Cell 60:941-951(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2).
RX   PubMed=2038316; DOI=10.1128/mcb.11.6.3052;
RA   Pleiman C.M., Gimpel S.D., Park L.S., Harada H., Taniguchi T.,
RA   Ziegler S.F.;
RT   "Organization of the murine and human interleukin-7 receptor genes: two
RT   mRNAs generated by differential splicing and presence of a type I-
RT   interferon-inducible promoter.";
RL   Mol. Cell. Biol. 11:3052-3059(1991).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1), INVOLVEMENT IN T(-)B(+)NK(+)
RP   SCID, AND VARIANTS THR-66; ILE-138 AND ILE-244.
RX   PubMed=9843216; DOI=10.1038/3877;
RA   Puel A., Ziegler S.F., Buckley R.H., Leonard W.J.;
RT   "Defective IL7R expression in T(-)B(+)NK(+) severe combined
RT   immunodeficiency.";
RL   Nat. Genet. 20:394-397(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 4), AND VARIANTS
RP   THR-66; ILE-138 AND VAL-356.
RC   TISSUE=Spleen;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1), AND VARIANTS THR-66;
RP   ASP-113; ILE-138 AND ILE-244.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (OCT-2003) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15372022; DOI=10.1038/nature02919;
RA   Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S.,
RA   Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M.,
RA   She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S.,
RA   Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M.,
RA   Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T., Gomez M.,
RA   Gonzales E., Goodstein D., Grigoriev I., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Israni S., Jett J., Kadner K., Kimball H., Kobayashi A.,
RA   Lopez F., Lou Y., Martinez D., Medina C., Morgan J., Nandkeshwar R.,
RA   Noonan J.P., Pitluck S., Pollard M., Predki P., Priest J., Ramirez L.,
RA   Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., Thayer N.,
RA   Tice H., Tsai M., Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J.,
RA   Dickson M., Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A.,
RA   Rokhsar D.S., Richardson P., Lucas S.M., Myers R.M., Rubin E.M.;
RT   "The DNA sequence and comparative analysis of human chromosome 5.";
RL   Nature 431:268-274(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANTS THR-66;
RP   ILE-138 AND VAL-356.
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 21-239 IN COMPLEX WITH IL7,
RP   SUBUNIT, GLYCOSYLATION AT ASN-49; ASN-65 AND ASN-151, AND DISULFIDE BONDS.
RX   PubMed=19141282; DOI=10.1016/j.str.2008.10.019;
RA   McElroy C.A., Dohm J.A., Walsh S.T.;
RT   "Structural and biophysical studies of the human IL-7/IL-7Ralpha complex.";
RL   Structure 17:54-65(2009).
RN   [9]
RP   INVOLVEMENT IN T(-)B(+)NK(+) SCID, AND VARIANT T(-)B(+)NK(+) SCID SER-132.
RX   PubMed=11023514;
RA   Roifman C.M., Zhang J., Chitayat D., Sharfe N.;
RT   "A partial deficiency of interleukin-7R alpha is sufficient to abrogate T-
RT   cell development and cause severe combined immunodeficiency.";
RL   Blood 96:2803-2807(2000).
RN   [10]
RP   VARIANT ILE-244, AND ASSOCIATION WITH MS3.
RX   PubMed=17660817; DOI=10.1038/ng2103;
RA   Gregory S.G., Schmidt S., Seth P., Oksenberg J.R., Hart J., Prokop A.,
RA   Caillier S.J., Ban M., Goris A., Barcellos L.F., Lincoln R., McCauley J.L.,
RA   Sawcer S.J., Compston D.A., Dubois B., Hauser S.L., Garcia-Blanco M.A.,
RA   Pericak-Vance M.A., Haines J.L.;
RT   "Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional
RT   association with multiple sclerosis.";
RL   Nat. Genet. 39:1083-1091(2007).
CC   -!- FUNCTION: Receptor for interleukin-7. Also acts as a receptor for
CC       thymic stromal lymphopoietin (TSLP).
CC   -!- SUBUNIT: The IL7 receptor is a heterodimer of IL7R and IL2RG. The TSLP
CC       receptor is a heterodimer of CRLF2 and IL7R.
CC       {ECO:0000269|PubMed:19141282}.
CC   -!- INTERACTION:
CC       P16871; Q6RW13-2: AGTRAP; NbExp=3; IntAct=EBI-80490, EBI-11522760;
CC       P16871; O95236-2: APOL3; NbExp=3; IntAct=EBI-80490, EBI-11976321;
CC       P16871; P27449: ATP6V0C; NbExp=3; IntAct=EBI-80490, EBI-721179;
CC       P16871; Q8IX05: CD302; NbExp=3; IntAct=EBI-80490, EBI-14259393;
CC       P16871; Q92520: FAM3C; NbExp=3; IntAct=EBI-80490, EBI-2876774;
CC       P16871; P13232: IL7; NbExp=10; IntAct=EBI-80490, EBI-80516;
CC       P16871; Q13021: MALL; NbExp=3; IntAct=EBI-80490, EBI-750078;
CC       P16871; P11836: MS4A1; NbExp=3; IntAct=EBI-80490, EBI-2808234;
CC       P16871; P31431: SDC4; NbExp=3; IntAct=EBI-80490, EBI-3913237;
CC       P16871; A0PK00: TMEM120B; NbExp=3; IntAct=EBI-80490, EBI-10171534;
CC       P16871; Q9H2L4: TMEM60; NbExp=3; IntAct=EBI-80490, EBI-2852148;
CC       P16871; O95183: VAMP5; NbExp=3; IntAct=EBI-80490, EBI-10191195;
CC   -!- SUBCELLULAR LOCATION: [Isoform 1]: Cell membrane; Single-pass type I
CC       membrane protein.
CC   -!- SUBCELLULAR LOCATION: [Isoform 3]: Cell membrane; Single-pass type I
CC       membrane protein.
CC   -!- SUBCELLULAR LOCATION: [Isoform 4]: Secreted.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1; Synonyms=H20;
CC         IsoId=P16871-1; Sequence=Displayed;
CC       Name=3; Synonyms=H1;
CC         IsoId=P16871-2; Sequence=VSP_001714;
CC       Name=4; Synonyms=H6, Secreted;
CC         IsoId=P16871-3; Sequence=VSP_001713;
CC       Name=2; Synonyms=Secreted;
CC         IsoId=P16871-4; Sequence=VSP_012618, VSP_012619;
CC   -!- DOMAIN: The WSXWS motif appears to be necessary for proper protein
CC       folding and thereby efficient intracellular transport and cell-surface
CC       receptor binding.
CC   -!- DOMAIN: The box 1 motif is required for JAK interaction and/or
CC       activation.
CC   -!- PTM: N-glycosylated IL-7Ralpha binds IL7 300-fold more tightly than the
CC       unglycosylated form. {ECO:0000269|PubMed:19141282}.
CC   -!- DISEASE: Severe combined immunodeficiency autosomal recessive T-cell-
CC       negative/B-cell-positive/NK-cell-positive (T(-)B(+)NK(+) SCID)
CC       [MIM:608971]: A form of severe combined immunodeficiency (SCID), a
CC       genetically and clinically heterogeneous group of rare congenital
CC       disorders characterized by impairment of both humoral and cell-mediated
CC       immunity, leukopenia, and low or absent antibody levels. Patients
CC       present in infancy recurrent, persistent infections by opportunistic
CC       organisms. The common characteristic of all types of SCID is absence of
CC       T-cell-mediated cellular immunity due to a defect in T-cell
CC       development. {ECO:0000269|PubMed:11023514, ECO:0000269|PubMed:9843216}.
CC       Note=The disease is caused by variants affecting the gene represented
CC       in this entry.
CC   -!- DISEASE: Multiple sclerosis 3 (MS3) [MIM:612595]: A multifactorial,
CC       inflammatory, demyelinating disease of the central nervous system.
CC       Sclerotic lesions are characterized by perivascular infiltration of
CC       monocytes and lymphocytes and appear as indurated areas in pathologic
CC       specimens (sclerosis in plaques). The pathological mechanism is
CC       regarded as an autoimmune attack of the myelin sheath, mediated by both
CC       cellular and humoral immunity. Clinical manifestations include visual
CC       loss, extra-ocular movement disorders, paresthesias, loss of sensation,
CC       weakness, dysarthria, spasticity, ataxia and bladder dysfunction.
CC       Genetic and environmental factors influence susceptibility to the
CC       disease. {ECO:0000269|PubMed:17660817}. Note=Disease susceptibility is
CC       associated with variants affecting the gene represented in this entry.
CC       A polymorphism at position 244 strongly influences susceptibility to
CC       multiple sclerosis. Overtransmission of the major 'C' allele coding for
CC       Thr-244 is detected in offspring affected with multiple sclerosis. In
CC       vitro analysis of transcripts from minigenes containing either 'C'
CC       allele (Thr-244) or 'T' allele (Ile-244) shows that the 'C' allele
CC       results in an approximately two-fold increase in the skipping of exon
CC       6, leading to increased production of a soluble form of IL7R. Thus, the
CC       multiple sclerosis associated 'C' risk allele of IL7R would probably
CC       decrease membrane-bound expression of IL7R. As this risk allele is
CC       common in the general population, some additional triggers are probably
CC       required for the development and progression of MS.
CC   -!- SIMILARITY: Belongs to the type I cytokine receptor family. Type 4
CC       subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH20717.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=IL7Rbase; Note=IL7R mutation db;
CC       URL="http://structure.bmc.lu.se/idbase/IL7Rbase/";
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/il7r/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M29696; AAA59157.1; -; mRNA.
DR   EMBL; AF043129; AAC83204.1; -; Genomic_DNA.
DR   EMBL; AF043123; AAC83204.1; JOINED; Genomic_DNA.
DR   EMBL; AF043124; AAC83204.1; JOINED; Genomic_DNA.
DR   EMBL; AF043125; AAC83204.1; JOINED; Genomic_DNA.
DR   EMBL; AF043126; AAC83204.1; JOINED; Genomic_DNA.
DR   EMBL; AF043127; AAC83204.1; JOINED; Genomic_DNA.
DR   EMBL; AF043128; AAC83204.1; JOINED; Genomic_DNA.
DR   EMBL; AK301220; BAG62793.1; -; mRNA.
DR   EMBL; AK315251; BAG37673.1; -; mRNA.
DR   EMBL; AY449709; AAR08908.1; -; Genomic_DNA.
DR   EMBL; AC112204; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC020717; AAH20717.1; ALT_SEQ; mRNA.
DR   EMBL; BC067537; AAH67537.1; -; mRNA.
DR   EMBL; BC067538; AAH67538.1; -; mRNA.
DR   EMBL; BC067539; AAH67539.1; -; mRNA.
DR   EMBL; BC067540; AAH67540.1; -; mRNA.
DR   EMBL; BC069999; AAH69999.1; -; mRNA.
DR   CCDS; CCDS3911.1; -. [P16871-1]
DR   PIR; A34791; A34791.
DR   PIR; B34791; B34791.
DR   PIR; C34791; C34791.
DR   RefSeq; NP_002176.2; NM_002185.3. [P16871-1]
DR   PDB; 3DI2; X-ray; 2.70 A; B/D=21-239.
DR   PDB; 3DI3; X-ray; 2.90 A; B=21-239.
DR   PDB; 3UP1; X-ray; 2.15 A; A/B=21-239.
DR   PDB; 5J11; X-ray; 2.56 A; B=21-236.
DR   PDB; 6P50; X-ray; 2.90 A; C=21-239.
DR   PDB; 6P67; X-ray; 2.90 A; G/I/J/K=21-239.
DR   PDBsum; 3DI2; -.
DR   PDBsum; 3DI3; -.
DR   PDBsum; 3UP1; -.
DR   PDBsum; 5J11; -.
DR   PDBsum; 6P50; -.
DR   PDBsum; 6P67; -.
DR   SASBDB; P16871; -.
DR   SMR; P16871; -.
DR   BioGRID; 109789; 130.
DR   DIP; DIP-3045N; -.
DR   ELM; P16871; -.
DR   IntAct; P16871; 18.
DR   STRING; 9606.ENSP00000306157; -.
DR   GuidetoPHARMACOLOGY; 1698; -.
DR   GlyGen; P16871; 6 sites.
DR   iPTMnet; P16871; -.
DR   PhosphoSitePlus; P16871; -.
DR   BioMuta; IL7R; -.
DR   DMDM; 215274000; -.
DR   MassIVE; P16871; -.
DR   PaxDb; P16871; -.
DR   PeptideAtlas; P16871; -.
DR   PRIDE; P16871; -.
DR   ProteomicsDB; 53396; -. [P16871-1]
DR   ProteomicsDB; 53397; -. [P16871-2]
DR   ProteomicsDB; 53398; -. [P16871-3]
DR   ProteomicsDB; 53399; -. [P16871-4]
DR   ABCD; P16871; 4 sequenced antibodies.
DR   Antibodypedia; 4129; 1300 antibodies.
DR   DNASU; 3575; -.
DR   Ensembl; ENST00000303115; ENSP00000306157; ENSG00000168685. [P16871-1]
DR   Ensembl; ENST00000506850; ENSP00000421207; ENSG00000168685. [P16871-3]
DR   GeneID; 3575; -.
DR   KEGG; hsa:3575; -.
DR   UCSC; uc003jjs.5; human. [P16871-1]
DR   CTD; 3575; -.
DR   DisGeNET; 3575; -.
DR   GeneCards; IL7R; -.
DR   HGNC; HGNC:6024; IL7R.
DR   HPA; ENSG00000168685; Group enriched (blood, intestine, lung, lymphoid tissue).
DR   MalaCards; IL7R; -.
DR   MIM; 146661; gene.
DR   MIM; 608971; phenotype.
DR   MIM; 612595; phenotype.
DR   neXtProt; NX_P16871; -.
DR   OpenTargets; ENSG00000168685; -.
DR   Orphanet; 39041; Omenn syndrome.
DR   Orphanet; 169154; T-B+ severe combined immunodeficiency due to IL-7Ralpha deficiency.
DR   PharmGKB; PA29840; -.
DR   VEuPathDB; HostDB:ENSG00000168685.14; -.
DR   eggNOG; ENOG502S4WE; Eukaryota.
DR   GeneTree; ENSGT00510000048500; -.
DR   HOGENOM; CLU_045398_0_0_1; -.
DR   InParanoid; P16871; -.
DR   OMA; KPIVWPS; -.
DR   OrthoDB; 617812at2759; -.
DR   PhylomeDB; P16871; -.
DR   TreeFam; TF336573; -.
DR   PathwayCommons; P16871; -.
DR   Reactome; R-HSA-1266695; Interleukin-7 signaling.
DR   Reactome; R-HSA-8856825; Cargo recognition for clathrin-mediated endocytosis.
DR   Reactome; R-HSA-8856828; Clathrin-mediated endocytosis.
DR   SignaLink; P16871; -.
DR   SIGNOR; P16871; -.
DR   BioGRID-ORCS; 3575; 1 hit in 988 CRISPR screens.
DR   ChiTaRS; IL7R; human.
DR   EvolutionaryTrace; P16871; -.
DR   GeneWiki; Interleukin-7_receptor-%CE%B1; -.
DR   GenomeRNAi; 3575; -.
DR   Pharos; P16871; Tbio.
DR   PRO; PR:P16871; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   RNAct; P16871; protein.
DR   Bgee; ENSG00000168685; Expressed in blood and 174 other tissues.
DR   ExpressionAtlas; P16871; baseline and differential.
DR   Genevisible; P16871; HS.
DR   GO; GO:0030669; C:clathrin-coated endocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0009897; C:external side of plasma membrane; IEA:Ensembl.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0003823; F:antigen binding; TAS:ProtInc.
DR   GO; GO:0004896; F:cytokine receptor activity; IDA:UniProtKB.
DR   GO; GO:0004917; F:interleukin-7 receptor activity; TAS:ProtInc.
DR   GO; GO:0042100; P:B cell proliferation; IEA:Ensembl.
DR   GO; GO:0000902; P:cell morphogenesis; IEA:Ensembl.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0050830; P:defense response to Gram-positive bacterium; IEA:Ensembl.
DR   GO; GO:0048872; P:homeostasis of number of cells; IEA:Ensembl.
DR   GO; GO:0006955; P:immune response; TAS:ProtInc.
DR   GO; GO:0038111; P:interleukin-7-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0048535; P:lymph node development; IEA:Ensembl.
DR   GO; GO:0061024; P:membrane organization; TAS:Reactome.
DR   GO; GO:0070233; P:negative regulation of T cell apoptotic process; IEA:Ensembl.
DR   GO; GO:0001915; P:negative regulation of T cell mediated cytotoxicity; IEA:Ensembl.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IDA:UniProtKB.
DR   GO; GO:0010628; P:positive regulation of gene expression; IEA:Ensembl.
DR   GO; GO:1904894; P:positive regulation of receptor signaling pathway via STAT; IDA:UniProtKB.
DR   GO; GO:0033089; P:positive regulation of T cell differentiation in thymus; IEA:Ensembl.
DR   GO; GO:0008361; P:regulation of cell size; IEA:Ensembl.
DR   GO; GO:0000018; P:regulation of DNA recombination; TAS:ProtInc.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0030217; P:T cell differentiation; IEA:Ensembl.
DR   CDD; cd00063; FN3; 1.
DR   Gene3D; 2.60.40.10; -; 1.
DR   InterPro; IPR040997; FN3_7.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR036116; FN3_sf.
DR   InterPro; IPR003531; Hempt_rcpt_S_F1_CS.
DR   InterPro; IPR013783; Ig-like_fold.
DR   Pfam; PF00041; fn3; 1.
DR   Pfam; PF18447; FN3_7; 1.
DR   SUPFAM; SSF49265; SSF49265; 1.
DR   PROSITE; PS50853; FN3; 1.
DR   PROSITE; PS01355; HEMATOPO_REC_S_F1; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell membrane; Disease variant;
KW   Disulfide bond; Glycoprotein; Membrane; Phosphoprotein; Receptor;
KW   Reference proteome; SCID; Secreted; Signal; Transmembrane;
KW   Transmembrane helix.
FT   SIGNAL          1..20
FT   CHAIN           21..459
FT                   /note="Interleukin-7 receptor subunit alpha"
FT                   /id="PRO_0000010909"
FT   TOPO_DOM        21..239
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        240..264
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        265..459
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          131..231
FT                   /note="Fibronectin type-III"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   MOTIF           217..221
FT                   /note="WSXWS motif"
FT   MOTIF           272..280
FT                   /note="Box 1 motif"
FT   COMPBIAS        184..189
FT                   /note="Ser/Thr-rich"
FT   MOD_RES         282
FT                   /note="Phosphothreonine; by PKC"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        49
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19141282"
FT   CARBOHYD        65
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19141282"
FT   CARBOHYD        151
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19141282"
FT   CARBOHYD        182
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        232
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        233
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        42..57
FT                   /evidence="ECO:0000269|PubMed:19141282"
FT   DISULFID        74..82
FT                   /evidence="ECO:0000269|PubMed:19141282"
FT   DISULFID        108..118
FT                   /evidence="ECO:0000269|PubMed:19141282"
FT   VAR_SEQ         237..459
FT                   /note="EMDPILLTISILSFFSVALLVILACVLWKKRIKPIVWPSLPDHKKTLEHLCK
FT                   KPRKNLNVSFNPESFLDCQIHRVDDIQARDEVEGFLQDTFPQQLEESEKQRLGGDVQSP
FT                   NCPSEDVVITPESFGRDSSLTCLAGNVSACDAPILSSSRSLDCRESGKNGPHVYQDLLL
FT                   SLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSLGSNQEEAYVTMSSFYQNQ -> LS
FT                   LSYGPVSPIIRRLWNIFVRNQEK (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_001713"
FT   VAR_SEQ         237..252
FT                   /note="EMDPILLTISILSFFS -> LSLSYGPVSPIIRQEL (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:2038316"
FT                   /id="VSP_012618"
FT   VAR_SEQ         253..459
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:2038316"
FT                   /id="VSP_012619"
FT   VAR_SEQ         293..459
FT                   /note="NLNVSFNPESFLDCQIHRVDDIQARDEVEGFLQDTFPQQLEESEKQRLGGDV
FT                   QSPNCPSEDVVITPESFGRDSSLTCLAGNVSACDAPILSSSRSLDCRESGKNGPHVYQD
FT                   LLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSLGSNQEEAYVTMSSFYQNQ ->
FT                   VSVFGA (in isoform 3)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_001714"
FT   VARIANT         66
FT                   /note="I -> T (in dbSNP:rs1494558)"
FT                   /evidence="ECO:0000269|PubMed:14702039,
FT                   ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:2317865,
FT                   ECO:0000269|PubMed:9843216, ECO:0000269|Ref.5"
FT                   /id="VAR_021286"
FT   VARIANT         113
FT                   /note="E -> D (in dbSNP:rs11567735)"
FT                   /evidence="ECO:0000269|Ref.5"
FT                   /id="VAR_021287"
FT   VARIANT         132
FT                   /note="P -> S (in T(-)B(+)NK(+) SCID; dbSNP:rs104893894)"
FT                   /evidence="ECO:0000269|PubMed:11023514"
FT                   /id="VAR_034870"
FT   VARIANT         138
FT                   /note="V -> I (in dbSNP:rs1494555)"
FT                   /evidence="ECO:0000269|PubMed:14702039,
FT                   ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:2317865,
FT                   ECO:0000269|PubMed:9843216, ECO:0000269|Ref.5"
FT                   /id="VAR_021288"
FT   VARIANT         244
FT                   /note="T -> I (in dbSNP:rs6897932)"
FT                   /evidence="ECO:0000269|PubMed:17660817,
FT                   ECO:0000269|PubMed:9843216, ECO:0000269|Ref.5"
FT                   /id="VAR_021289"
FT   VARIANT         356
FT                   /note="I -> V (in dbSNP:rs3194051)"
FT                   /evidence="ECO:0000269|PubMed:14702039,
FT                   ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:2038316,
FT                   ECO:0000269|PubMed:2317865"
FT                   /id="VAR_021290"
FT   VARIANT         414
FT                   /note="T -> M (in dbSNP:rs2229232)"
FT                   /id="VAR_047742"
FT   CONFLICT        39
FT                   /note="S -> T (in Ref. 7; AAH67539)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        52
FT                   /note="Q -> R (in Ref. 7; AAH67538)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        384
FT                   /note="S -> P (in Ref. 7; AAH67537)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        386
FT                   /note="R -> G (in Ref. 7; AAH67539)"
FT                   /evidence="ECO:0000305"
FT   HELIX           35..38
FT                   /evidence="ECO:0007744|PDB:3UP1"
FT   STRAND          40..49
FT                   /evidence="ECO:0007744|PDB:3UP1"
FT   STRAND          52..61
FT                   /evidence="ECO:0007744|PDB:3UP1"
FT   STRAND          69..79
FT                   /evidence="ECO:0007744|PDB:3UP1"
FT   STRAND          81..84
FT                   /evidence="ECO:0007744|PDB:3UP1"
FT   STRAND          86..88
FT                   /evidence="ECO:0007744|PDB:3UP1"
FT   STRAND          91..97
FT                   /evidence="ECO:0007744|PDB:3UP1"
FT   STRAND          102..111
FT                   /evidence="ECO:0007744|PDB:3UP1"
FT   STRAND          114..122
FT                   /evidence="ECO:0007744|PDB:3UP1"
FT   HELIX           123..125
FT                   /evidence="ECO:0007744|PDB:3UP1"
FT   STRAND          133..140
FT                   /evidence="ECO:0007744|PDB:3UP1"
FT   TURN            141..144
FT                   /evidence="ECO:0007744|PDB:3UP1"
FT   STRAND          145..151
FT                   /evidence="ECO:0007744|PDB:3UP1"
FT   HELIX           153..156
FT                   /evidence="ECO:0007744|PDB:3UP1"
FT   STRAND          158..160
FT                   /evidence="ECO:0007744|PDB:3UP1"
FT   STRAND          163..173
FT                   /evidence="ECO:0007744|PDB:3UP1"
FT   STRAND          179..191
FT                   /evidence="ECO:0007744|PDB:3UP1"
FT   HELIX           192..194
FT                   /evidence="ECO:0007744|PDB:3UP1"
FT   STRAND          200..209
FT                   /evidence="ECO:0007744|PDB:3UP1"
FT   STRAND          211..213
FT                   /evidence="ECO:0007744|PDB:3DI3"
FT   STRAND          224..227
FT                   /evidence="ECO:0007744|PDB:3UP1"
SQ   SEQUENCE   459 AA;  51579 MW;  EF50BF2615EEF50C CRC64;
     MTILGTTFGM VFSLLQVVSG ESGYAQNGDL EDAELDDYSF SCYSQLEVNG SQHSLTCAFE
     DPDVNITNLE FEICGALVEV KCLNFRKLQE IYFIETKKFL LIGKSNICVK VGEKSLTCKK
     IDLTTIVKPE APFDLSVVYR EGANDFVVTF NTSHLQKKYV KVLMHDVAYR QEKDENKWTH
     VNLSSTKLTL LQRKLQPAAM YEIKVRSIPD HYFKGFWSEW SPSYYFRTPE INNSSGEMDP
     ILLTISILSF FSVALLVILA CVLWKKRIKP IVWPSLPDHK KTLEHLCKKP RKNLNVSFNP
     ESFLDCQIHR VDDIQARDEV EGFLQDTFPQ QLEESEKQRL GGDVQSPNCP SEDVVITPES
     FGRDSSLTCL AGNVSACDAP ILSSSRSLDC RESGKNGPHV YQDLLLSLGT TNSTLPPPFS
     LQSGILTLNP VAQGQPILTS LGSNQEEAYV TMSSFYQNQ
//
